Literature DB >> 24011719

Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog.

V Isella1, C Mapelli, N Morielli, C Siri, D De Gaspari, G Pezzoli, A Antonini, M Poletti, U Bonuccelli, L Picchi, A Napolitano, M Vista, I M Appollonio.   

Abstract

The detection of cognitive decline in Parkinson's disease (PD), at the Mild Cognitive Impairment (MCI) stage, has prognostic and treatment implications. The Movement Disorders Society (MDS) has recently published criteria and guidelines for the diagnosis of possible and probable PD-MCI. In the present study we assessed the ability of the Scales for Outcomes in Parkinson's disease-Cognition (SCOPA-Cog) to discriminate possible PD-MCI cases from patients with PD-dementia (PDD) and from cognitively intact PD subjects. Hundred-and-thirteen consecutive PD patients underwent the MMSE, the Dementia Rating Scale and an interview on independence in daily living, and were classified as cognitively intact (n = 49), or as possible PD-MCI (n = 33) or PDD (n = 31), according to MDS criteria. Logistic regression analysis was carried out with PD-MCI diagnosis (yes/no) as an outcome variable, and age, education and the SCOPA-Cog total score as covariates. Classification of cases according to the regression model was used for constructing Receiver Operating Characteristic (ROC) curves. Area Under the Curve (AUC) was 0.92 [95% CI 0.86-0.98], for the differential diagnosis between PD-MCI and cognitively normal patients, and 0.97 [95% CI 0.80-1.00], for the differential diagnosis between PD-MCI and PDD. Sensitivity and specificity were 90% and 73% for the PD-MCI versus no cognitive impairment differentiation, at the cutpoint ≥24, and 93% and 97% for the PD-MCI versus PDD discrimination, at the cutpoint ≥17. The SCOPA-Cog is a quick and psychometrically sound PD-specific scale. Our findings support its use for the screening of possible PD-MCI.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dementia; Mild Cognitive Impairment; Parkinson's disease; SCOPA-Cog

Mesh:

Year:  2013        PMID: 24011719     DOI: 10.1016/j.parkreldis.2013.08.008

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Authors:  Anne-Marie A Wills; Jordan J Elm; Rong Ye; Kelvin L Chou; Sotirios A Parashos; Robert A Hauser; Ivan Bodis-Wollner; Vanessa K Hinson; Chadwick W Christine; Jay S Schneider
Journal:  Parkinsonism Relat Disord       Date:  2016-10-08       Impact factor: 4.891

2.  Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Authors:  Achinoam Faust-Socher; Sarah Duff-Canning; Arthur Grabovsky; Melissa J Armstrong; Brandon Rothberg; Paul J Eslinger; Christopher A Meaney; Ruth B Schneider; David F Tang-Wai; Susan H Fox; Cindy Zadikoff; Nancy Kennedy; Kelvin L Chou; Carol Persad; Irene Litvan; Benjamin T Mast; Adam T Gerstenecker; Sandra Weintraub; William Reginold; Connie Marras
Journal:  Dement Geriatr Cogn Disord       Date:  2019-07-17       Impact factor: 2.959

Review 3.  Psychometrics and diagnostics of Italian cognitive screening tests: a systematic review.

Authors:  Edoardo Nicolò Aiello; Sara Rimoldi; Nadia Bolognini; Ildebrando Appollonio; Giorgio Arcara
Journal:  Neurol Sci       Date:  2021-11-24       Impact factor: 3.830

4.  The Montreal Cognitive Assessment: Is It Suitable for Identifying Mild Cognitive Impairment in Parkinson's Disease?

Authors:  Sara Rosenblum; Sonya Meyer; Netta Gemerman; Lilya Mentzer; Ariella Richardson; Simon Israeli-Korn; Vered Livneh; Tsvia Fay Karmon; Tal Nevo; Gilad Yahalom; Sharon Hassin-Baer
Journal:  Mov Disord Clin Pract       Date:  2020-06-25

5.  ReadySteady intervention to promote physical activity in older adults with Parkinson's disease: Study design and methods.

Authors:  Narayanan Krishnamurthi; Julie Fleury; Michael Belyea; Holly A Shill; James J Abbas
Journal:  Contemp Clin Trials Commun       Date:  2020-01-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.